Journal of International Psychiatry

Objective: To compare the efficacy and safety of amisulpride and quetiapine in the treatment of schizophrenia. Methods: Sixty cases of patients with schizophrenia in our hospital from August 2016 to August 2018 were randomly selected and randomly divided into two groups: a group of amisulpride (30 cases) and a group of quetiapine groups (30 cases). The PNASS scores, clinical efficacy, occurrances of adverse reactions of the two groups were statistically analyzed. Results: The general psychopathology, positive symptoms, negative symptom scores and PANSS scores after treatment of the two groups were significantly lower than before treatment (P<0.05). The differences of general psychopathology, positive symptoms, and negative symptom scores and total scores of PANSS before and after treatment between the two groups were not significant (P>0.05). The difference of total effective rate of treatment between the amisulpride group and quetiapine group 90.0% (27/30), 86.7% (26/30) was not significant (P>0.05). The incidence of adverse reactions of the amisulpride group 23.3% (7/30) was significantly lower than the quetiapine group 43.3% (13/30) (P<0.05). Conclusion: Amisulpride is equivalent to quetiapine in the treatment of schizophrenia, but amisulpride is safer than quetiapine, so is worthy of promotion and application in the clinical.

Amisulpride; Quetiapine; Schizophrenia; Efficacy; Safety